Trial Profile
Evaluation of patients reported outcomes after switching to single tablet regimen of rilpivirine/emtricitabine/tenofovir disoproxil fumarate in HIV infected patients: A 48-week observational study
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 25 May 2018
Price :
$35
*
At a glance
- Drugs Emtricitabine/rilpivirine/tenofovir disoproxil fumarate (Primary)
- Indications HIV infections
- Focus Adverse reactions
- Acronyms PRO-STR
- 16 May 2018 Results of a sub-analysis assessing lipid changes and tolerability, published in the Journal of Antimicrobial Chemotherapy
- 01 Mar 2016 New trial record